Faron Pharmaceuticals Oy
("Faron" or the "Company")
Faron secures U.S. rights to patent related to Traumakine
Company announcement, 14 May 2021 at 9.00 AM (EEST)
TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that it has signed a sub-license agreement for the rights to U.S. patent US9,376,478, which currently extends to 2033.